Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 3, 2008, Pages

  Mascarell, Laurent ^a   Lombardi, Vincent ^a   Louise, Anne ^b   Saint Lu, Nathalie ^a   Chabre, Henri ^a   Moussu, Hélène ^a   Betbeder, Didier ^c   Balazuc, Anne Marie ^b   Van Overtvelt, Laurence ^a   Moingeon, Philippe ^a  

^a Stallergenes SA   (France)

^b INSTITUT PASTEUR   (France)

^c UNIV LILLE   (France)

Author keywords

dendritic cell; mucosal immunity; sublingual immunotherapy

Indexed keywords

BIOTIN; DOXORUBICIN; GAMMA INTERFERON; INTERLEUKIN 10; OVALBUMIN; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; IMMUNOHISTOLOGY; MOUSE; MOUTH MUCOSA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL;

EID: 50649122989     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.06.034     Document Type: Article

References (38)

1. Wilson D.R., Torres L.I., and Durham S.R. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev (2003) CD002893
2. Passalacqua G., Guerra L., Pasquali M., Lombardi C., and Canonica G.W. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 93 (2004) 3-12
3. Pajno G.B., Peroni D.G., Vita D., Pietrobelli A., Parmiani S., and Boner A.L. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs 5 (2003) 777-781
4. Penagos M., Compalati E., Tarantini F., Baena-Cagnani R., Huerta J., Passalacqua G., et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 97 (2006) 141-148
5. Mascarell L., Van Overtvelt L., and Moingeon P. Novel ways for immune intervention in immunotherapy: mucosal allergy vaccines. Immunol Allergy Clin North Am 26 (2006) 283-306 vii-viii
6. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118 (2006) 434-440
7. Didier A., Malling H.J., Worm M., Horak F., Jager S., Montagut A., et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 120 (2007) 1338-1345
8. Razafindratsita A., Saint-Lu N., Mascarell L., Berjont N., Bardon T., Betbeder D., et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 120 (2007) 278-285
9. Allam J.P., Novak N., Fuchs C., Asen S., Berge S., Appel T., et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 112 (2003) 141-148
10. Allam J.P., Peng W.M., Appel T., Wenghoefer M., Niederhagen B., Bieber T., et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 121 (2008) 368-374
11. Durham S.R., and Till S.J. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 102 (1998) 157-164
12. El Biaze M., Boniface S., Koscher V., Mamessier E., Dupuy P., Milhe F., et al. T cell activation, from atopy to asthma: more a paradox than a paradigm. Allergy 58 (2003) 844-853
13. Ippoliti F., De Santis W., Volterrani A., Lenti L., Canitano N., Lucarelli S., et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 14 (2003) 216-221
14. Mavroleon G. Restoration of cytokine imbalance by immunotherapy. Clin Exp Allergy 28 (1998) 917-920
15. Hamid Q.A., Schotman E., Jacobson M.R., Walker S.M., and Durham S.R. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 99 (1997) 254-260
16. Benjaponpitak S., Oro A., Maguire P., Marinkovich V., DeKruyff R.H., and Umetsu D.T. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 103 (1999) 468-475
17. Ebner C., Siemann U., Bohle B., Willheim M., Wiedermann U., Schenk S., et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 27 (1997) 1007-1015
18. Secrist H., Chelen C.J., Wen Y., Marshall J.D., and Umetsu D.T. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 178 (1993) 2123-2130
19. Laaksonen K., Junikka M., Lahesmaa R., Terho E.O., and Savolainen J. In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J Allergy Clin Immunol 112 (2003) 1171-1177
20. Meissner N., Kochs S., Coutelle J., Kussebi F., Baumgarten C., Lowenstein H., et al. Modified T-cell activation pattern during specific immunotherapy (SIT) in cat-allergic patients. Clin Exp Allergy 29 (1999) 618-625
21. Majori M., Caminati A., Corradi M., Brianti E., Scarpa S., and Pesci A. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy 30 (2000) 341-347
22. Gabrielsson S., Soderlund A., Paulie S., van der Pouw Kraan T.C., Troye-Blomberg M., and Rak S. Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. Allergy 56 (2001) 293-300
23. Norman P.S. Immunotherapy: 1999-2004. J Allergy Clin Immunol 113 (2004) 1013-1023 quiz 24
24. Jutel M., Akdis M., Budak F., Aebischer-Casaulta C., Wrzyszcz M., Blaser K., et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 33 (2003) 1205-1214
25. Gardner L.M., Thien F.C., Douglass J.A., Rolland J.M., and O'Hehir R.E. Induction of T "regulatory" cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy 34 (2004) 1209-1219
26. Taylor A., Verhagen J., Akdis C.A., and Akdis M. T regulatory cells in allergy and health: a question of allergen specificity and balance. Int Arch Allergy Immunol 135 (2004) 73-82
27. Ciprandi G., Fenoglio D., Cirillo I., Vizzaccaro A., Ferrera A., Tosca M.A., et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 95 (2005) 38-44
28. Jonuleit H., Schmitt E., Schuler G., Knop J., and Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192 (2000) 1213-1222
29. Menges M., Rossner S., Voigtlander C., Schindler H., Kukutsch N.A., Bogdan C., et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 195 (2002) 15-21
30. Oldenhove G., de Heusch M., Urbain-Vansanten G., Urbain J., Maliszewski C., Leo O., et al. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med 198 (2003) 259-266
31. Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198 (2003) 235-247
32. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25 (2007) 8598-8610
33. Novak N., Bieber T., and Katoh N. Engagement of Fc epsilon RI on human monocytes induces the production of IL-10 and prevents their differentiation in dendritic cells. J Immunol 167 (2001) 797-804
34. Bohle B., Kinaciyan T., Gerstmayr M., Radakovics A., Jahn-Schmid B., and Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 120 (2007) 707-713
35. Cosmi L., Santarlasci V., Angeli R., Liotta F., Maggi L., Frosali F., et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy 36 (2006) 261-272
36. Savolainen J., Jacobsen L., and Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 61 (2006) 1184-1190
37. Lombardi V., Van Overtvelt L., Horiot S., Moussu H., Chabre H., Louise A., et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy Jul 17 (2008) [epub ahead of print]
38. Mascarell L., Van Overtvelt L., Lombardi V., Razafindratsita A., Moussu H., Horiot S., et al. A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route. Vaccine 26 (2007) 108-118